VIRTUOZZO
5.10.2021 13:02:10 CEST | Business Wire | Press release
Virtuozzo , a high-efficiency virtualization and hyperconverged infrastructure software leader, today announced it has acquired the technology and business of Jelastic , a multi-cloud Platform-as-a-Service (PaaS) software company, following a 10-year partnership.
Bringing Jelastic’s platform and application management capabilities in-house completes Virtuozzo’s core technology stack, delivering a fully integrated solution that supports all relevant anything-as-a-service (XaaS) use cases—from shared hosting to VPS to cloud infrastructure, software-defined storage and application management and modernization.
Virtuozzo offers the first fully integrated, easy-to-use and cost-efficient cloud solution designed for Cloud Service Providers, Managed Service Providers, Hosting Service Providers and their small and medium-sized business (SMB) customers. Virtuozzo also helps service providers increase profitability by providing a comprehensive portfolio of services and management tools.
Many PaaS vendors focus on a single-purpose offering. Jelastic, however, offers a robust, multi-purpose solution that, via the acquisition, will position Virtuozzo as a strong player in the PaaS market and further strengthen Virtuozzo’s position overall in the rapidly growing cloud services space.
“Virtuozzo and Jelastic have been strong partners over the past 10 years because of our complementary technologies and products,” said Alex Fine, CEO of Virtuozzo. “Virtuozzo containers have been incorporated into Jelastic’s Platform-as-a-Service for virtualization since that solution’s inception. Together, our engineering teams have co-developed solutions to enable features required by the market throughout our partnership. And now, with Jelastic joining our team, Virtuozzo can offer a complete, enterprise-grade, turnkey cloud enablement platform with fully integrated orchestration and a single point of management.”
Service Providers Want Simplicity, Automation and Choice
Service providers demand simplification and automation in container and cloud management. Jelastic has been providing a proven production-ready platform to cover these needs for years. The acquisition enables tighter integration and seamless enhancements.
In addition, service providers require a wider set of products to offer to end users. “Freedom of choice” is the core mantra that runs throughout the Jelastic ecosystem. Customers can choose various solutions and services, different types of workloads and management through an automated orchestration.
“Our companies are completely aligned and deeply understand the challenges and opportunities in the service provider industry where Platform-as-a-Service enablement is the key in the process of SaaS-ification and digitalization of its customers,” said Jelastic CEO Ruslan Synytsky. “Our joint partners will benefit from this acquisition since together we become a one-stop shop for Anything-as-a-Service, making it easier to get whatever they need for their users. The joint forces will accelerate the innovation and product development cycles. Together we can raise the bar for the industry standards with the help of our unique technologies that solve real problems of the cloud users.”
Platform-as-a-Service Market Shows Strong Growth
In 2022, the PaaS market is estimated to be worth approximately $71 billion U.S. dollars based on Gartner research . Cloud services (such as PaaS) are anticipated to grow by a high margin at around 27%.
The increased adoption of PaaS among service providers is driven by the end-users’ demand for access to easy-to-manage, high performing and scalable solutions.
By acquiring Jelastic, Virtuozzo can help its service provider partners achieve high ROI by both attracting new end-users and retaining existing customers through enabling XaaS use cases, providing more advanced automation and simplifying their own DevOps processes.
Business as Usual
Business continues as usual, with Jelastic now operating as a division of Virtuozzo—underscoring the value in Jelastic’s brand and technologies. Ruslan Synytsky has been appointed to Chief Technology Officer of Virtuozzo.
Integration of Jelastic’s sales and marketing teams will expand Virtuozzo’s worldwide footprint and brand visibility; and integration of Jelastic’s engineering resources will enable Virtuozzo to accelerate its full stack offering and provide a richer experience across multiple cloud providers.
Terms of the transaction were not disclosed.
About Jelastic
Jelastic is a Multi-Cloud DevOps PaaS for ISVs, telcos, service providers and enterprises needing to speed up development, reduce cost of IT infrastructure, improve uptime and security. The platform automates creation, scaling, clustering and security updates of cloud-native and traditional applications. Jelastic has a unique pay-as-you-use pricing model and is available as public, private, hybrid and multi-cloud in more than 100 data centers worldwide. The platform supports Java, PHP, Ruby, Node.js, Python, .NET, Go environments, as well as Docker and Kubernetes clusters.
About Virtuozzo
Virtuozzo (www.virtuozzo.com ) is a leading, global provider of hybrid virtualization, storage, and cloud enablement software solutions. The Company's software-defined, hyperconverged self-service platform and resource management capabilities enable hosting and service providers to provide end-customers with public and private cloud services. Virtuozzo is an industry pioneer who developed the first commercially available container technology 21 years ago. The Company provides software solutions and services to over 750 service providers worldwide. A significant force in the open-source community, Virtuozzo sponsors and/or is a contributor to numerous open-source projects including KVM, Docker, OpenStack, OpenVZ, CRIU, and the Linux kernel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005403/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom